Table 2 Clinical outcomes of patients with OAL treated with ultra-low-dose RT
From: Ultra-low-dose radiotherapy in the treatment of ocular adnexal lymphoma: a prospective study
Comm treatment | Patients (n = 16), n (%) |
|---|---|
Follow-up Time (mo) | |
Median (range) | 15.5 (5.0–30.0) |
Best corrective visual acuity | |
Baseline, Median (range) | 20/35 (20/20-LP) |
Final, Median (range) | 20/30 (20/20-HM) |
Lesion Area (mm2) | |
Baseline | 203.8 ± 92.2 |
Post-operation | 117.9 ± 60.4* |
Initial evaluation post-RT | 38.7 ± 46.0# |
One year post RT (n = 13) | |
With regression (n = 11) | 8.5 ± 21.2# |
With recurrence (n = 2) | 191.7 ± 13.9 |
Local response at initial evaluation (n = 16) | |
Complete regression | 9 (56) |
Partial regression | 7 (44) |
Progression | 0 (0) |
Local response at 6 months (n = 14) | |
Complete regression | 11 (79) |
Partial regression | 2 (14) |
Progression | 1 (7) |
Time to Complete regression (mo) | |
Median (range) | 2.0 (1.0–7.3) |
Time to recurrence (mo) | |
Median (range) | 7.5 (3.0–12.0) |
Disease status at last follow-up | |
Complete regression | 13 (81) |
Alive with disease | 3 (19) |
Dead due to lymphoma | 0 (0) |
Dead due to causes other than lymphoma | 0 (0) |
Progression-free survival at one year (%) | 85 |
Progression-free survival (mo) | |
Median (range) | 15.5 (5.0–24.0) |
Ocular toxicity (n = 16) | |
Acute toxic effect | 0 (0) |
Chronic toxic effect | 0 (0) |